PT-141 (Bremelanotide) Bone Health and Density Impact

What Bremelanotide Is and How It Works

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist that activates MC1R, MC3R, MC4R, and MC5R with high affinity, and MC2R (the ACTH receptor) to a lesser degree [1]. The FDA approved it in June 2019 under the brand name Vyleesi for acquired, generalized HSDD in premenopausal women [2]. Unlike flibanserin (Addyi), which works through central serotonin and dopamine pathways on a daily schedule, bremelanotide is taken on an as-needed basis and cleared within several hours.

Mechanism at the Melanocortin System

The drug's pro-sexual effect is mediated centrally, primarily through hypothalamic MC4R activation, which modulates dopaminergic reward circuitry [3]. MC3R co-activation may blunt appetite-related signaling. The nausea that affects roughly 40% of users is also MC-receptor-mediated, arising from area-postrema and nucleus tractus solitarius activity [4].

Why Bone Researchers Pay Attention to MC Receptors

Melanocortin receptors are not confined to the brain. Human osteoblasts and osteoclasts express MC1R and MC2R, and rodent models show that MC2R activation by ACTH suppresses osteoclast activity independent of glucocorticoid signaling [5]. This observation generated early theoretical concern that any potent MC-receptor agonist might perturb bone remodeling. Whether bremelanotide, at its approved dose and frequency, produces sufficient skeletal MC-receptor occupancy to matter clinically is a separate and more nuanced question.

The RECONNECT Trial: What the Data Actually Show

The phase 3 RECONNECT program comprised two identically designed randomized, double-blind, placebo-controlled trials published in Obstetrics and Gynecology in 2019 [1]. Combined enrollment was 1,247 premenopausal women with diagnosed HSDD. Participants self-administered 1.75 mg bremelanotide or placebo subcutaneously for 24 weeks.

Primary Efficacy Outcomes

The co-primary endpoints were change from baseline in the Female Sexual Function Index desire domain score and change in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 score. Bremelanotide produced a statistically significant improvement versus placebo on both measures (P<0.001 for each co-primary endpoint) [1]. The magnitude of benefit was modest in absolute terms, a pattern consistent with other centrally acting agents in this indication.

Safety Reporting and Bone Outcomes

Bone mineral density (BMD) was not a pre-specified endpoint in RECONNECT. No fractures, significant BMD loss, or osteopenia progression were reported as adverse events of interest during the 24-week observation window [1]. The FDA prescribing information for Vyleesi does not list bone loss among warnings, precautions, or adverse reactions [2].

This absence of a signal is meaningful but not definitive. Twenty-four weeks is short relative to the years-long timeline over which meaningful BMD changes accumulate on bone-active drugs. The as-needed dosing schedule also limits cumulative receptor occupancy. A woman using bremelanotide once or twice per week accumulates far less total melanocortin receptor stimulation than a patient receiving continuous-infusion melanocortin therapy in an experimental setting.

Transient Blood Pressure Effect

One cardiovascular finding from RECONNECT is relevant to a broader safety discussion: bremelanotide transiently raises systolic blood pressure by a mean of 6 mmHg and diastolic blood pressure by 3 mmHg, peaking at approximately 12 minutes post-dose and resolving within 12 hours [2]. Because sustained hypertension is itself a risk factor for secondary hyperparathyroidism and bone loss in some populations, clinicians should confirm cardiovascular stability before prescribing.

Melanocortin Receptors and Bone Biology

Understanding why clinicians sometimes ask about bone effects requires a short review of MC-receptor function in skeletal tissue.

MC1R in Osteoblasts

MC1R is expressed on human osteoblast precursors and mature osteoblasts. Alpha-melanocyte-stimulating hormone (alpha-MSH), the endogenous ligand that bremelanotide structurally mimics, has been shown in vitro to promote osteoblast differentiation and reduce osteoblast apoptosis [6]. If anything, this action would be expected to support rather than harm bone formation. Bremelanotide shares sequence homology with alpha-MSH and activates MC1R, though its pharmacokinetic profile differs from the very short half-life of endogenous alpha-MSH.

MC2R, ACTH, and Cortisol-Independent Bone Effects

MC2R is the ACTH receptor. Exogenous ACTH administration at supraphysiologic doses (as used in some rheumatology protocols) suppresses osteoclastogenesis in rodents through direct skeletal MC2R signaling, independent of adrenal cortisol release [5]. This mechanism does not obviously apply to bremelanotide, which has low MC2R affinity at therapeutic concentrations. Still, it illustrates that the melanocortin system has real, receptor-mediated effects on bone remodeling that are not simply downstream of cortisol.

MC4R and Energy Balance Connections to Bone

MC4R mutations in humans cause severe obesity, and obesity itself has a complex relationship with bone density. Leptin, adiponectin, and insulin signaling all intersect with MC4R pathways and with osteoblast function [7]. Bremelanotide activates MC4R centrally. Whether intermittent hypothalamic MC4R stimulation at therapeutic doses alters the downstream hormonal milieu enough to affect bone over months or years has not been studied prospectively.

Estrogen Status and the Real Bone Risk in HSDD Patients

HSDD in premenopausal women is frequently associated with hormonal disturbances. Low estrogen, whether from hypothalamic amenorrhea, perimenopause, or iatrogenic causes, is the dominant modifiable driver of bone loss in this age group [8]. Bremelanotide is approved only for premenopausal women, but "premenopausal" includes women with low estradiol from stress, athletic overtraining, or hyperprolactinemia.

A prescriber evaluating bone health in a woman starting bremelanotide should focus first on her estrogen status, not on bremelanotide's direct skeletal effects. The 2023 NAMS Position Statement on menopause management states that "estrogen therapy remains the most effective treatment for vasomotor symptoms and is also effective in preventing bone loss in early postmenopausal women" [9]. The same estrogenic deficiency that drives HSDD in some patients is the mechanism most likely to erode BMD.

When to Order DEXA in a Bremelanotide Candidate

The U.S. Preventive Services Task Force recommends DEXA screening for all women aged 65 and older and for younger postmenopausal women with a 10-year fracture risk (FRAX score) equivalent to that of a 65-year-old white woman [10]. For premenopausal women, the International Society for Clinical Densitometry recommends DEXA when a secondary cause of low bone mass is suspected, including prolonged amenorrhea, glucocorticoid use, or malabsorptive conditions [11].

Bremelanotide itself does not yet meet the threshold of a "secondary cause" requiring DEXA. Clinicians should order DEXA based on the patient's underlying hormonal and nutritional status, not because of the bremelanotide prescription.

Concurrent Medications That Do Affect Bone

Many women with HSDD are also taking selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) for mood or anxiety disorders. SSRIs are associated with reduced BMD (OR approximately 1.6 for fracture in observational data) [12]. Proton pump inhibitors, common co-prescriptions, impair calcium absorption and carry a modest fracture risk in long-term users [13]. These co-prescriptions represent a more immediate, evidence-supported bone concern than bremelanotide itself.

Off-Label Use and Dose-Escalation: The Unanswered Question

Bremelanotide is used off-label for erectile dysfunction in men at doses ranging from 1.75 mg to 2 mg, and in some telehealth contexts at higher or more frequent doses than the FDA label specifies [14]. The RECONNECT safety database does not cover these patterns.

Higher Doses and MC2R Engagement

At doses above approximately 2 mg, bremelanotide's affinity for MC2R becomes clinically relevant. Sustained MC2R activation could theoretically stimulate adrenal cortisol output. Even modest cortisol elevations sustained over months are associated with BMD reduction; a 5 mcg/dL increase in morning cortisol correlates with roughly 1.5% annual bone loss in some observational series [15]. This is theoretical for bremelanotide at currently used off-label doses, but it is mechanistically plausible and warrants monitoring in patients using the drug more frequently or at higher doses than approved.

Lack of Long-Term Safety Data

No phase 3 trial has followed bremelanotide users for longer than 52 weeks with bone endpoints. A 2022 review in the Journal of Sexual Medicine noted that "long-term safety data for bremelanotide, particularly regarding cardiovascular and endocrine outcomes, remain limited" [14]. Bone density falls squarely within this gap.

Practical Prescribing Guidance for Bone-Conscious Clinicians

The following recommendations reflect current evidence and are intended as a clinical framework pending longer-term data.

Before Starting Bremelanotide

Assess estrogen status with serum estradiol and FSH in any premenopausal woman with irregular cycles or suspected hypoestrogenism. Address calcium and vitamin D adequacy: serum 25-hydroxyvitamin D should be at least 30 ng/mL per Endocrine Society guidelines [16]. Order baseline DEXA only if the patient meets established ISCD or USPSTF criteria independent of bremelanotide use.

During Treatment

Stick to the approved dose of 1.75 mg per use, no more than one dose per 24 hours. There is no bone-specific monitoring interval mandated by the FDA label. Reassess fracture risk annually using FRAX if the patient has one or more clinical risk factors.

If Higher or More Frequent Off-Label Dosing Is Used

Check a morning serum cortisol at 3 and 6 months if the patient uses doses above 1.75 mg or more than 8 doses per month. This threshold is not evidence-based from a bremelanotide-specific trial; it is extrapolated from the MC2R pharmacology discussed above and should be treated as precautionary rather than standard of care.

Comparing Bremelanotide to Other HSDD Treatments: Bone Safety Profile

Flibanserin, the other FDA-approved HSDD drug, acts on 5-HT1A, 5-HT2A, and dopamine D4 receptors and has no known direct interaction with bone metabolism [17]. Its daily CNS serotonergic activity might theoretically affect serotonin-mediated osteoblast regulation (serotonin receptors are expressed on osteoblasts), but no clinically meaningful BMD reduction has been documented in its clinical trial program.

Hormone-based approaches, such as off-label testosterone supplementation or estrogen optimization, have well-characterized bone effects. Testosterone at supraphysiologic doses in women can modestly increase BMD through aromatization to estradiol [18]. Low-dose testosterone at physiologic ranges shows more variable skeletal effects.

Bremelanotide's bone safety profile, while incompletely characterized for long-term use, is currently more favorable than that of SSRIs or glucocorticoids often encountered as co-medications in the same patient population.

Summary of Evidence Gaps and Research Priorities

Clinicians and patients deserve honest acknowledgment of what remains unknown.

No randomized trial has measured BMD as a primary or secondary endpoint in bremelanotide users. All available inference comes from receptor pharmacology, animal studies, and the absence of bone-related adverse event reports in a 24-week trial. That 24-week window, while adequate for demonstrating efficacy, is insufficient to detect the kind of gradual BMD decline that would be clinically meaningful.

Future research priorities should include a 12-month open-label extension with DXA endpoints, measurement of bone turnover markers (serum CTX and P1NP) in frequent users, and pharmacokinetic modeling of MC2R occupancy at off-label doses to determine whether adrenal stimulation is pharmacologically achievable under real-world dosing patterns.

Pending that data, the RECONNECT trial's 24-week safety record supports the conclusion that bremelanotide at 1.75 mg as-needed does not carry a detectable acute bone risk, while the mechanistic literature justifies ongoing vigilance for patients using the drug at higher doses or greater frequency than the label specifies.